HOME > NATION > Article

Text Size

small

medium

large


Hopes High in Japan for New Alzheimer's Drug

Hopes High in Japan for New Alzheimer's Drug

   Tokyo, June 8 (Jiji Press)--Hopes are high in Japan that the new Alzheimer's disease drug developed jointly by Eisai Co. <4523> and U.S. biopharmaceutical company Biogen Inc. will ease burdens on patients and their families.
   Dementia is a serious social problem in Japan, where the population is aging rapidly, as it involves physically demanding caregiving by family members and high treatment costs.
   The new remedy, aducanumab, is expected to ease such burdens, while there are concerns that it may drive up the country's medical costs.
   The number of people with dementia in Japan is seen rising from 4.62 million in 2012 to 7.3 million in 2025. Some experts estimate that two in three of them will have Alzheimer's disease.
   According to Eisai and others, the disease cost Japanese society over 12 trillion yen in 2018, more than half of which was related to caregiving by family members.

To read a full story, please click here to find out how to subscribe.

NATION

Aomori Tourism Information

HEADLINES

POLITICS
Leading Opposition CDP to Downgrade Consumption Tax Cut Pledge to "Target"
ECONOMY
Japan Starts Minting New 500-Yen Coins
SPORTS
10,000-Spectator Ceiling Set for Tokyo Games
OTHER
Woman Referred to Prosecutors for Insulting TV Personality Chiemi Hori Online

AFP-JIJI PRESS NEWS JOURNAL


Photos